MarketCap
Facebook
X
Telegram
Innate Pharma S.A. Balance Sheet 2025-2011 | IPHA
Brief overview of Innate Pharma S.A.'s financial position
This overview follows the five latest available annual observations between 2016 and 2020.
Across five periods, assets reached €307.4 million versus €281.6 million initially. Growth of +9.2% reflects gradual development.
Liabilities grew more slowly than assets: -22.5% versus +9.2%. Expansion relied more on equity, improving funding quality.
Equity accounts for 50.7% of assets. Against the initial , the capital position looks resilient.
Cash exceeds interest-bearing debt, producing net debt of -€119.8 million. The balance sheet therefore carries a net cash position.
The accumulated result is -€220.5 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Conclusion
Innate Pharma S.A. shows a high-quality balance sheet profile, with adequate internal capital and room for maneuver.
Annual Balance Sheet Innate Pharma S.A.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | - | - | -120 M | -189 M | -150 M | -96.5 M | -174 M | -151 M | -57.8 M | -36.7 M | -29.8 M | -33.4 M |
Long Term Debt |
- | - | - | - | - | 16.9 M | 14.1 M | 2.03 M | 2.42 M | 1.05 M | 1.35 M | 1.5 M | 1.5 M | 131 K | - |
Total Non Current Liabilities |
47.8 M | 69.2 M | 83.6 M | 104 M | - | 105 M | - | 87.2 M | 95.2 M | 119 M | 174 M | 5.29 M | 6.32 M | 9.57 M | 18 M |
Total Liabilities |
- | - | - | - | - | 151 M | 184 M | 284 M | 169 M | 195 M | 234 M | 16.1 M | 15.6 M | 24.9 M | 33.5 M |
Deferred Revenue |
- | - | - | - | - | 12.5 M | 91.8 M | 82.1 M | 47.9 M | 54.9 M | - | 885 K | 1.26 M | 7.66 M | - |
Retained Earnings |
- | - | - | - | - | -220 M | -156 M | -135 M | -152 M | -104 M | -116 M | -110 M | -90 M | -87.1 M | -6.98 M |
Total Assets |
62.7 M | 111 M | 175 M | 199 M | 267 M | 307 M | 401 M | 451 M | 255 M | 282 M | 306 M | 90.7 M | 55.9 M | 48.3 M | 60.1 M |
Cash and Cash Equivalents |
28.1 M | 66.4 M | 70.6 M | 84.2 M | 104 M | 137 M | 203 M | 152 M | 99.4 M | - | - | - | - | - | - |
Book Value |
62.7 M | 111 M | 175 M | 199 M | 267 M | 156 M | 217 M | 167 M | 86 M | 86.2 M | 72.1 M | 74.6 M | 40.3 M | 23.4 M | 26.6 M |
Total Shareholders Equity |
-21.7 M | 8.83 M | 51.9 M | 54.2 M | - | 156 M | 217 M | 167 M | 86 M | - | - | - | - | - | - |
All numbers in EUR currency
Quarterly Balance Sheet Innate Pharma S.A.
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Non Current Liabilities |
47.8 M | 58.4 M | 69.2 M | 84.5 M | 83.6 M | 104 M | - | - | - | - | 80.2 M | - | 90 M | - | 106 M | - | - | - | 62.1 M | - | - | - | 87.2 M | - | - | - | 95.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -135 M | - | - | - | -139 M | - | - | - | -104 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
62.7 M | 92.9 M | 111 M | 151 M | 175 M | 199 M | - | - | - | - | 267 M | - | 266 M | - | 307 M | - | - | - | 401 M | - | - | - | 451 M | - | - | - | 255 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
28.1 M | 53.7 M | 66.4 M | 70 M | 70.6 M | 71.4 M | - | - | - | - | 104 M | - | 104 M | - | 137 M | - | 132 M | - | 203 M | - | - | - | 152 M | - | - | - | 99.4 M | - | - | - | 176 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
62.7 M | 92.9 M | 111 M | 151 M | 175 M | 199 M | - | - | - | - | 267 M | - | 266 M | - | 307 M | - | - | - | 401 M | - | - | - | 451 M | - | - | - | 255 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-21.7 M | 5.14 M | 8.83 M | 28.8 M | 51.9 M | 57.9 M | - | - | - | - | 107 M | - | 134 M | - | 156 M | - | 208 M | - | 217 M | - | - | - | 167 M | - | - | - | 99.4 M | - | - | - | 86.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Balance Sheet is a fundamental financial report of Innate Pharma S.A., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Russia
USA
Canada
Germany
China
Israel
France
Britain
Belgium
